ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the antibodies contract manufacturing industry with an estimated share of 38.2% in 2024 can be attributed to a strong presence of key market players and continuous support from the government for pharmaceutical research and development. Additionally, strategic collaborations between global pharmaceutical companies and contract manufacturers have boosted regional production capabilities.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth due to expanding biologics industry, increasing outsourcing of drug development activities by pharmaceutical companies, and favorable government policies supporting contract manufacturing. Countries like China and India offer low-cost alternatives for producing biologics which is attracting significant investments.

Antibodies Contract Manufacturing Market Outlook for Key Countries

U.S.’ substantial R&D investments in biologics

The U.S. antibodies contract manufacturing industry showcases global dominance driven by substantial R&D investments in biologics and a robust pipeline of the U.S. FDA-approved biologic drugs. With over 900 biologic candidates in clinical trials, the steady increase in new approvals has expanded market opportunities. This growth is bolstered by extensive R&D resources, a focus on innovation, and a well-established regulatory framework, fueling the demand for antibodies contract manufacturing services.

Germany’s market leads in Europe, driven by active biopharmaceutical research

Germany leads the Europe antibodies contract manufacturing industry, with its biopharmaceutical sector actively advancing antibodies-drug conjugate (ADC) research. In September 2022, Tubulis GmbH, in collaboration with the German Cancer Consortium (DKTK), the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), and LMU Klinikum Munich, demonstrated the high efficacy and safety of ADCs in preclinical models of Acute Myeloid Leukemia (AML). This research is expected to enhance ADC development in Germany, supporting market growth in the coming years.

Japan leads Asia Pacific's antibodies contract manufacturing industry with heavy investments in antibody drug development

Japan continues to lead Asia Pacific’s antibodies contract manufacturing market on the back of heavy investments in antibodies drug development. Local manufacturers are gaining prominence through strategic tie-ups with global drug developers. For instance, In September 2021, GlaxoSmithKline K.K. (GSK Japan) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) granted Special Approval for Emergency (SAE) for Xevudy (sotrovimab), a monoclonal antibodies treatment for mild to moderate COVID-19.

India's Rising Prominence in Antibody Contract Manufacturing

India antibodies contract manufacturing market is strengthening its position in the Asia Pacific region, propelled by cost-effective production and growing expertise in biosimilars and vaccine development. The nation's skilled workforce and advanced biomanufacturing infrastructure facilitate large-scale, competitively priced production for both domestic and international markets. Government initiatives like "Make in India" promote foreign investment by establishing a supportive regulatory framework aligned with global standards, streamlining processes and enhancing India's appeal for antibodies production.